EGFR and non-small cell lung carcinoma: As for the possible prognostic advantage of an upfront RT treatment followed by TKI therapy, [90] out of a multicentric series of 351 patients with BM from EGFR mutated NSCLC, 100 patients were treated with SRS followed by TKI therapy achieved the best therapeutic results (median survival, respectively, 46, 30, and 25 months; p < 0.001), compared to 120 with WBRT followed by TKI, and 131 with TKI followed by SRS or WBRT at progression.